Search research articles
Contact Us
Filters
Showing results (161-170 of 206) with videos related to
Page
of 21
Sort By:
Eclinicalmedicine
|
August 9, 2023
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
John R Jones, David A Cairns, Tom Menzies, et al.
Blood
|
May 22, 2020
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials
Charlotte A Bradbury, Zoe Craig, Gordon Cook, et al.
Leukemia
|
July 3, 2013
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
Brian A Walker, Christopher P Wardell, Lorenzo Melchor, et al.
BMC Cancer
|
July 27, 2022
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
G Sommerhäuser, A Kurreck, S Stintzing, et al.
Haematologica
|
April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)
Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
Blood
|
November 28, 2014
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
Charlotte Pawlyn, Lorenzo Melchor, Alex Murison, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO
M M Germani, V Heinemann, D Rossini, et al.
Blood Cancer Journal
|
April 1, 2017
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
C Pawlyn, M D Bright, A F Buros, et al.
Leukemia
|
March 12, 2020
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
Vallari Shah, Amy L Sherborne, David C Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2022
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
Ruth M de Tute, Charlotte Pawlyn, David A Cairns, et al.
Page
of 21
Search research articles
Search
Showing results (161-170 of 206) with videos related to
Sort By:
Page
of 21
Eclinicalmedicine
|
August 9, 2023
Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
John R Jones, David A Cairns, Tom Menzies, et al.
Blood
|
May 22, 2020
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials
Charlotte A Bradbury, Zoe Craig, Gordon Cook, et al.
Leukemia
|
July 3, 2013
Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms
Brian A Walker, Christopher P Wardell, Lorenzo Melchor, et al.
BMC Cancer
|
July 27, 2022
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
G Sommerhäuser, A Kurreck, S Stintzing, et al.
Haematologica
|
April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)
Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
Blood
|
November 28, 2014
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations
Charlotte Pawlyn, Lorenzo Melchor, Alex Murison, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 21, 2025
Risk of disease progression in the first-line therapy of metastatic colorectal cancer to guide disease re-assessments - analysis of eleven trials by AIO and GONO
M M Germani, V Heinemann, D Rossini, et al.
Blood Cancer Journal
|
April 1, 2017
Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
C Pawlyn, M D Bright, A F Buros, et al.
Leukemia
|
March 12, 2020
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
Vallari Shah, Amy L Sherborne, David C Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 4, 2022
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk
Ruth M de Tute, Charlotte Pawlyn, David A Cairns, et al.
Page
of 21